{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:34Z","timestamp":1793398234713,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01282-0","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:21:10Z","timestamp":1745425270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-0614","authenticated-orcid":false,"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloise","family":"Cheruvalath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Clennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineel","family":"Bhatlapenumarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anannya","family":"Patwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metodi","family":"Balev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asis","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Trikannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Vellanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al-Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-2380","authenticated-orcid":false,"given":"Aishee","family":"Bag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-5643","authenticated-orcid":false,"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6745","authenticated-orcid":false,"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"1282_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl J Med. 2022;387:495\u2013505.","journal-title":"N. Engl J Med"},{"key":"1282_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1282_CR3","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N. Engl J Med. 2022;387:2232\u201344.","journal-title":"N. Engl J Med"},{"key":"1282_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/hematology.2023000433","volume":"2023","author":"H Lee","year":"2023","unstructured":"Lee H, Neri P, Bahlis NJ. Current use of bispecific antibodies to treat multiple myeloma. Hematology. 2023;2023:332\u20139.","journal-title":"Hematology"},{"key":"1282_CR5","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898\u2013903.","journal-title":"Blood Adv"},{"key":"1282_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3324\/haematol.2023.283590","volume":"109","author":"L Hammons","year":"2023","unstructured":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023;109:906\u201314.","journal-title":"Haematologica"},{"key":"1282_CR7","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D\u2019Souza A, et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022;6:2466\u201370.","journal-title":"Blood Adv"},{"key":"1282_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01091-x","volume":"14","author":"AJ Yee","year":"2024","unstructured":"Yee AJ. Improving outcomes with anti-BCMA bispecific antibodies with attention to infection. Blood Cancer J. 2024;14:110.","journal-title":"Blood Cancer J"},{"key":"1282_CR9","doi-asserted-by":"publisher","first-page":"e2238961-e","DOI":"10.1001\/jamanetworkopen.2022.38961","volume":"5","author":"LR Hammons","year":"2022","unstructured":"Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D\u2019Souza A, et al. Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. JAMA Netw Open. 2022;5:e2238961-e.","journal-title":"JAMA Netw Open"},{"key":"1282_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711\u201325.e6.","journal-title":"Cancer Cell"},{"key":"1282_CR11","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/bjh.19700","volume":"205","author":"OS Akhtar","year":"2024","unstructured":"Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, et al. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. Br J Haematol. 2024;205:1830\u201334.","journal-title":"Br J Haematol"},{"key":"1282_CR12","first-page":"1059","volume":"343","author":"HM Chapel","year":"1994","unstructured":"Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. UK Group Immunoglobulin Replacement Ther Mult Myeloma Lancet. 1994;343:1059\u201363.","journal-title":"UK Group Immunoglobulin Replacement Ther Mult Myeloma Lancet"},{"key":"1282_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","volume":"90","author":"P Blombery","year":"2011","unstructured":"Blombery P, Prince HM, Worth LJ, Main J, Yang M, Wood EM, et al. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Ann Hematol. 2011;90:1167\u201372.","journal-title":"Ann Hematol"},{"key":"1282_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ajh.22229","volume":"87","author":"JE Howell","year":"2012","unstructured":"Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol. 2012;87:172\u20134.","journal-title":"Am J Hematol"},{"key":"1282_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/tid.12424","volume":"17","author":"S Park","year":"2015","unstructured":"Park S, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K. Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma. Transpl Infect Dis. 2015;17:679\u201387.","journal-title":"Transpl Infect Dis"},{"key":"1282_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.13223","volume":"102","author":"IK Na","year":"2019","unstructured":"Na IK, Buckland M, Agostini C, Edgar JDM, Friman V, Michallet M, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019;102:447\u201356.","journal-title":"Eur J Haematol"},{"key":"1282_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01107-6","volume":"14","author":"A Wonnaparhown","year":"2024","unstructured":"Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R. IgG replacement in multiple myeloma. Blood Cancer J. 2024;14:124.","journal-title":"Blood Cancer J"},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023;4:440\u201351.","journal-title":"Blood Cancer Discov"},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24:e255\u2013e69.","journal-title":"Lancet Oncol"},{"key":"1282_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.","journal-title":"Blood Cancer J"},{"key":"1282_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.18909","volume":"203","author":"M Mohan","year":"2023","unstructured":"Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D'Souza A, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023;203:736\u201346.","journal-title":"Br J Haematol"},{"key":"1282_CR22","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, G\u00e1llego P\u00e9rez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205\u2013e16.","journal-title":"Lancet Oncol"},{"key":"1282_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35.","journal-title":"Blood Cancer J"},{"key":"1282_CR24","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1282_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520","volume":"44","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies. Am Soc Clin Oncol Educ Book. 2024;44:e433520.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1282_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1282_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med. 1984;3:35\u201344.","journal-title":"Stat Med"},{"key":"1282_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/01621459.1974.10480131","volume":"69","author":"N Mantel","year":"1974","unstructured":"Mantel N, Byar DP. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data. J Am Stat Assoc. 1974;69:81\u20136.","journal-title":"J Am Stat Assoc"},{"key":"1282_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886\u2013900.","journal-title":"Cancer"},{"key":"1282_CR30","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJM198810063191403","volume":"319","author":"RP Gale","year":"1988","unstructured":"Gale RP, Chapel HM, Bunch C, Rai KR, Foon K, Courter SG, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N. Engl J Med. 1988;319:902\u20137.","journal-title":"N. Engl J Med"},{"key":"1282_CR31","doi-asserted-by":"crossref","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book. 2019:39:433\u201344.","DOI":"10.1200\/EDBK_238691"},{"key":"1282_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13:399\u2013409.","journal-title":"Nat Rev Rheumatol"},{"key":"1282_CR33","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1200\/JCO.2024.42.16_suppl.7528","volume":"42","author":"RM Rifkin","year":"2024","unstructured":"Rifkin RM, Schade HH, Simmons G, Yasenchak CA, Fowler J, Lin TS, et al. OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42:7528.","journal-title":"J Clin Oncol"},{"key":"1282_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y","volume":"13","author":"SA Scott","year":"2023","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer J. 2023;13:191.","journal-title":"Blood Cancer J"},{"key":"1282_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01114-7","volume":"14","author":"R Chakraborty","year":"2024","unstructured":"Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, et al. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma. Blood Cancer J. 2024;14:137.","journal-title":"Blood Cancer J"},{"key":"1282_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1478-7547-8-14","volume":"8","author":"G Blackhouse","year":"2010","unstructured":"Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc. 2010;8:14.","journal-title":"Cost Eff Resour Alloc"},{"key":"1282_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-101","volume":"11","author":"JL Winters","year":"2011","unstructured":"Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome. BMC Health Serv Res. 2011;11:101.","journal-title":"BMC Health Serv Res"},{"key":"1282_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2024.02.013","volume":"24","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Cowan AJ, Ortega M, Missimer C, Carpenter PA, Oshima MU, et al. Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:446\u201354.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1282_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009220","volume":"12","author":"JH Frenking","year":"2024","unstructured":"Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer. 2024;12:e009220.","journal-title":"J Immunother Cancer"},{"key":"1282_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.","journal-title":"J Hematol Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01282-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:21:12Z","timestamp":1745425272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01282-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01282-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}